Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Biomea Fusion Inc. | Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211) | Diabetes and obesity | Phase 2b | Trial Planned | Oral | Endocrinology |
| Biomea Fusion Inc. | Icovamenib (BMF-219) - (COVALENT-112) | Type 1 diabetes (T1D) | Phase 2 | Clinical Hold | Oral | Endocrinology |
| Biomea Fusion Inc. | Icovamenib - (COVALENT-212) | Type 2 diabetes | Phase 2 | Trial Planned | Oral | Endocrinology |
| BiomX Inc. | BX211 | Diabetic foot osteomyelitis (DFO) | Phase 2 | Data Released | Oral | Orthopedic |
| BiomX Inc. | BX011 | Diabetic Foot Infections | Phase 2 | Trial Planned | Intravenous | Antibiotic |
| BiomX Inc. | BX001 | Acne | Phase 2 | Trial Discontinued | Topical | N/A |
| BiomX Inc. | BX004 | P. aeruginosa in patients with Cystic Fibrosis (CF) | Phase 2b | Trial Discontinued | Inhalation | Respiratory |
| Bionomics Limited | BNC210 - (ATTUNE) | Post-Traumatic Stress Disorder (PTSD) | Phase 3 | Trial Planned | Oral | Psychiatric |
